Santen Pharmaceutical Co Ltd (4536) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/santen-pharmaceutical-co-ltd-4536-financial-n-strategic-swot-analysis-review_en.gif)
Santen Pharmaceutical Co Ltd (4536) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through group companies in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.
Santen Pharmaceutical Co Ltd Key Recent Developments
May 18,2021: Glaukos expands its PRESERFLO MicroShunt relationship with Santen via new license agreement
May 11,2021: Santen Reports Fiscal 2020 Consolidated Financial Results for the Year Ended March 31, 2021
Apr 09,2021: Santen Pharmaceutical Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 06,2021: Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean
Feb 05,2021: Santen and IAPB partner to advocate for better eye health
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through group companies in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.
Santen Pharmaceutical Co Ltd Key Recent Developments
May 18,2021: Glaukos expands its PRESERFLO MicroShunt relationship with Santen via new license agreement
May 11,2021: Santen Reports Fiscal 2020 Consolidated Financial Results for the Year Ended March 31, 2021
Apr 09,2021: Santen Pharmaceutical Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 06,2021: Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean
Feb 05,2021: Santen and IAPB partner to advocate for better eye health
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Santen Pharmaceutical Co Ltd - Key Facts
Santen Pharmaceutical Co Ltd - Key Employees
Santen Pharmaceutical Co Ltd - Key Employee Biographies
Santen Pharmaceutical Co Ltd - Major Products and Services
Santen Pharmaceutical Co Ltd - History
Santen Pharmaceutical Co Ltd - Company Statement
Santen Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Santen Pharmaceutical Co Ltd - Business Description
Business Segment: Medical Devices
Overview
Performance
Business Segment: OTC Pharmaceuticals
Overview
Performance
Business Segment: Others
Performance
Business Segment: Prescription Pharmaceuticals
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia
Performance
Geographical Segment: China
Performance
Geographical Segment: EMEA
Performance
Geographical Segment: Japan
Performance
R&D Overview
Santen Pharmaceutical Co Ltd - Corporate Strategy
Santen Pharmaceutical Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Santen Pharmaceutical Co Ltd - Strengths
Santen Pharmaceutical Co Ltd - Weaknesses
Santen Pharmaceutical Co Ltd - Opportunities
Santen Pharmaceutical Co Ltd - Threats
Santen Pharmaceutical Co Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 18, 2021: Glaukos expands its PRESERFLO MicroShunt relationship with Santen via new license agreement
May 11, 2021: Santen Reports Fiscal 2020 Consolidated Financial Results for the Year Ended March 31, 2021
Apr 09, 2021: Santen Pharmaceutical Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 06, 2021: Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean
Feb 05, 2021: Santen and IAPB partner to advocate for better eye health
Feb 04, 2021: Santen reports the 3rd quarter fiscal 2020 consolidated performance
Jan 08, 2021: Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference
Dec 31, 2020: Santen Pharmaceutical: Summary of consolidated financial results for the nine months ended December 31, 2020
Nov 06, 2020: Santen reports the 2nd quarter fiscal 2020 consolidated performance
Oct 28, 2020: Santen, JBFA and IBF Foundation form long-term partnership for an inclusive society
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Santen Pharmaceutical Co Ltd - Key Facts
Santen Pharmaceutical Co Ltd - Key Employees
Santen Pharmaceutical Co Ltd - Key Employee Biographies
Santen Pharmaceutical Co Ltd - Major Products and Services
Santen Pharmaceutical Co Ltd - History
Santen Pharmaceutical Co Ltd - Company Statement
Santen Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Santen Pharmaceutical Co Ltd - Business Description
Business Segment: Medical Devices
Overview
Performance
Business Segment: OTC Pharmaceuticals
Overview
Performance
Business Segment: Others
Performance
Business Segment: Prescription Pharmaceuticals
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia
Performance
Geographical Segment: China
Performance
Geographical Segment: EMEA
Performance
Geographical Segment: Japan
Performance
R&D Overview
Santen Pharmaceutical Co Ltd - Corporate Strategy
Santen Pharmaceutical Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Santen Pharmaceutical Co Ltd - Strengths
Santen Pharmaceutical Co Ltd - Weaknesses
Santen Pharmaceutical Co Ltd - Opportunities
Santen Pharmaceutical Co Ltd - Threats
Santen Pharmaceutical Co Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 18, 2021: Glaukos expands its PRESERFLO MicroShunt relationship with Santen via new license agreement
May 11, 2021: Santen Reports Fiscal 2020 Consolidated Financial Results for the Year Ended March 31, 2021
Apr 09, 2021: Santen Pharmaceutical Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 06, 2021: Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean
Feb 05, 2021: Santen and IAPB partner to advocate for better eye health
Feb 04, 2021: Santen reports the 3rd quarter fiscal 2020 consolidated performance
Jan 08, 2021: Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference
Dec 31, 2020: Santen Pharmaceutical: Summary of consolidated financial results for the nine months ended December 31, 2020
Nov 06, 2020: Santen reports the 2nd quarter fiscal 2020 consolidated performance
Oct 28, 2020: Santen, JBFA and IBF Foundation form long-term partnership for an inclusive society
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Santen Pharmaceutical Co Ltd, Key Facts
Santen Pharmaceutical Co Ltd, Key Employees
Santen Pharmaceutical Co Ltd, Key Employee Biographies
Santen Pharmaceutical Co Ltd, Major Products and Services
Santen Pharmaceutical Co Ltd, History
Santen Pharmaceutical Co Ltd, Other Locations
Santen Pharmaceutical Co Ltd, Subsidiaries
Santen Pharmaceutical Co Ltd, Key Competitors
Santen Pharmaceutical Co Ltd, Ratios based on current share price
Santen Pharmaceutical Co Ltd, Annual Ratios
Santen Pharmaceutical Co Ltd, Annual Ratios (Cont...1)
Santen Pharmaceutical Co Ltd, Annual Ratios (Cont...2)
Santen Pharmaceutical Co Ltd, Interim Ratios
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Santen Pharmaceutical Co Ltd, Key Facts
Santen Pharmaceutical Co Ltd, Key Employees
Santen Pharmaceutical Co Ltd, Key Employee Biographies
Santen Pharmaceutical Co Ltd, Major Products and Services
Santen Pharmaceutical Co Ltd, History
Santen Pharmaceutical Co Ltd, Other Locations
Santen Pharmaceutical Co Ltd, Subsidiaries
Santen Pharmaceutical Co Ltd, Key Competitors
Santen Pharmaceutical Co Ltd, Ratios based on current share price
Santen Pharmaceutical Co Ltd, Annual Ratios
Santen Pharmaceutical Co Ltd, Annual Ratios (Cont...1)
Santen Pharmaceutical Co Ltd, Annual Ratios (Cont...2)
Santen Pharmaceutical Co Ltd, Interim Ratios
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Santen Pharmaceutical Co Ltd, Performance Chart (2017 - 2021)
Santen Pharmaceutical Co Ltd, Ratio Charts
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Performance Chart (2017 - 2021)
Santen Pharmaceutical Co Ltd, Ratio Charts
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021